Pfizer Inc.

NYSE:PFE   11:19:15 AM EDT
43.36
+0.39 (+0.91%)
Products

Ideaya Announces Dose Expansion In Study Of Ide196 And Binimetinib Combination In Metastatic Uveal Melanoma

Published: 03/23/2021 10:16 GMT
Pfizer Inc. (PFE) - Ideaya Announces Dose Expansion in Phase 1/2 Study of Ide196 and Binimetinib Combination in Metastatic Uveal Melanoma Based on Early Clinical Activity.
Ideaya Biosciences - Targeting Enrollment of About 40 Patients in Ide196 and Binimetinib Clinical Combination Phase 1/2 Study in Mum.
Ideaya Biosciences - Targeting Interim Data From Ide196 & Binimetinib Clinical Combination Arm in Mum in 2021.
Ideaya Biosciences - Targeting Interim Data From Ide196 Monotherapy Arm of Phase 1/2 Basket Trial in Mum and Gnaq/11-mutation Skin Melanoma in 2021.